Weekly Recap: Q2 beat and U.S. intravenous abatacept Dec 2026

What happened

Dr. Reddy’s Laboratories reported mixed Q2 FY27 results: revenue fell about 1% year over year, while EBITDA and net profit exceeded estimates. Gross margin reached 51.7%. The company expects a U.S. decision on its intravenous abatacept biosimilar in December 2026 and targets launches in the U.S. and Europe from fiscal 2028 onward.

Confirmed

Global impact / market context

Revenue declined, but stronger gross margin and results above estimates suggest improved profitability despite the weaker sales figure. If abatacept receives approval and launches as targeted, it could add sales from fiscal 2028; until then, its contribution depends on the U.S. decision and execution in the U.S. and Europe.

Analyst inference

The supplied recap shows different near-term and longer-term drivers: Q2 revenue was down about 1% year over year, while gross margin reached 51.7%, and the company is planning other product launches. Abatacept remains a future opportunity, not current reported revenue.

Analyst inference

What to watch

1. Watch upcoming results for whether revenue stabilizes and gross margin remains strong; that would indicate whether better profitability can persist despite the Q2 sales decline. Analyst inference
2. The company expects a U.S. decision on intravenous abatacept in December 2026 and targets U.S. and European launches, with sales from fiscal 2028 onward. Confirmed
3. Track semaglutide pen commercialization in Canada and selected international markets, alongside the stated sales plan, for signs that launches are translating into revenue. Analyst inference

Evidence

• Original source link unavailable